Gabby Dower

Gabby Dower has over a decade of experience in the biotechnology and pharmaceutical industry. Gabby began their career in 2004 as an Undergraduate Trainee at Unifesp - Universidade Federal de São Paulo, where they investigated pioglitazone as a candidate drug to attenuate nephrotoxicity in rats caused by long-term treatment with cyclosporine. In 2007, they became a Graduate Student at Universidade de São Paulo, where they studied the role of B1 bradykinin receptor in experimental models of direct and indirect acute lung injury. From 2009 to 2011, they were a Research Fellow and Exchange Graduate Student at Harvard Medical School - Brigham and Women's Hospital. From 2011 to 2013, they were a Postdoctoral Fellow at the University of Washington, where they designed and performed in vivo and in vitro experiments to study the role of macrophage activation in regeneration and fibrosis.

From 2013 to 2019, they worked at Pfizer as a Senior Principal Scientist in the Inflammation and Immunology Department - Discovery Biology Group. During their time at Pfizer, they were a Group Leader, a Project Leader for a lead optimization program, and the Biology Lead for a late stage IBD program. From 2019 to 2020, they worked at Celgene as a Principal Scientist, where they led a biology team evaluating multiple targets in autoimmune diseases, brought targets to Go/No-go decision points, and identified and assembled a Key Opinion Leader panel to provide input on an early target validation. Gabby is currently working at Mediar Therapeutics as an Associate Director - Fibrosis Biology.

Gabby Dower earned their B.S. in Biomedical Sciences from Universidade de Mogi das Cruzes between 2003 and 2006. Gabby then went on to receive their PhD in Immunology from USP - Universidade de São Paulo between 2007 and 2010.